Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Trastuzumab Deruxtecan +/- Anastrozole in HER2-low HR+ Breast Cancer
NCT04553770Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2020
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Oct 2020; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04553770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553770.